Nature Reviews Drug Discovery contents May 2013 Volume 12 Number 5 pp 325-404

Advertisement
NPG and Frontiers form alliance to further open science Frontiers is at the forefront of building the ultimate Open Science platform and is driving innovations around peer-review, article and author impact metrics and social networking for researchers. NPG and Frontiers will work together to empower researchers to change the way science is communicated. Find out more
TABLE OF CONTENTS
May 2013 Volume 12 Number 5
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Platforms for antibiotic discovery Kim Lewis
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Grant Funding for New Drug Discoveries Harrington Discovery Institute at UH Case Medical Center announces its 2013 Harrington Scholar-Innovator Grant competition, open to physician-scientists at accredited academic medical centers, research institutions and universities in the U.S. Letters of Intent due May 15, 2013. Learn more at www.HarringtonDiscovery.org.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
nature.com webcasts Macmillan Science Communication, presents a custom webcast on: Using microfluidics for real-time imaging of in vitro cell models Thursday May 30th 2013 8am PDT / 11am EDT / 4pm BST / 5pm CEST Register for free Sponsored by:
In this issue p325 | doi:10.1038/nrd4004 Full Text
Comment: Translational medicine: mitigating risks for investigators Douglas L. Mann & Daria Mochly-Rosen p327 | doi:10.1038/nrd4005 Academic biomedical scientists are increasingly being encouraged to engage in translational research. However, there are underappreciated downsides for investigators if their translational efforts do not lead to positive results in pivotal clinical trials. Full Text | PDF
NEWS AND ANALYSIS		Top
Maturing antibody-drug conjugate pipeline hits 30 Asher Mullard p329 | doi:10.1038/nrd4009 Driven by recent clinical breakthroughs and technological progress, 30 antibody-drug conjugates against over 24 targets are now in trials for blood cancers and solid tumours. PDF
NEWS IN BRIEF FDA issues Alzheimer's rethink p333 | doi:10.1038/nrd4024 PDF
Big expectations for Biogen's small MS drug p333 | doi:10.1038/nrd4025 PDF
Mini-Sentinel saves dabigatran p333 | doi:10.1038/nrd4026 PDF
BIOBUSINESS BRIEFS Trial watch: Sepsis study failure highlights need for trial design rethink Man Tsuey Tse p334 | doi:10.1038/nrd4016 PDF
BIOBUSINESS BRIEFS Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs Charlotte Harrison p335 | doi:10.1038/nrd4017 PDF
PATENT WATCH Indian Supreme Court blocks Novartis' Glivec patent | Tuberculosis Charlotte Harrison p336 | doi:10.1038/nrd4007 PDF
AN AUDIENCE WITH Henry Chesbrough Asher Mullard PDF
FROM THE ANALYST'S COUCH Commercial prospects for genomic sequencing technologies Sharmarke Mohamed & Basharut A. Syed p341 | doi:10.1038/nrd4006 This article analyses the evolution of the market for genomic sequencing technologies in the light of major reductions in sequencing costs and time, and the growth in potential pharmacogenomics applications. PDF
RESEARCH HIGHLIGHTS Top Tumour vaccination: Devil in the details of adjuvant choice p343 | doi:10.1038/nrd4014 PDF Kinase inhibitors: Double duty p344 | doi:10.1038/nrd4011 PDF Blood disorders: Boosting the stem cell harvest p344 | doi:10.1038/nrd4015 PDF Infectious diseases: Novel agents fight flu infection p345 | doi:10.1038/nrd4013 PDF Anticancer drugs: Presenting for service p346 | doi:10.1038/nrd4012 PDF IN BRIEF Lead identification: Better HSP90 inhibitors | Animal models: A speedy route to mutant mice | Vaccines: Bacterial minicells could offer safer vaccines | Anticoagulants: An antidote to factor Xa inhibitors PDF Drug Discovery JOBS of the week Postdoc in Drug Delivery and Biomaterials The Ohio State University (OSU) Research Chemist Institute for Shock Physics/Applied Sciences Laboratory/Washington State University Research Chemist Econic Technologies Structural / Organic Chemist Postdoctoral Fellow Boehringer Ingelheim Medicinal Chemist Team Leader Selvita More Science jobs from Drug Discovery EVENT Resources for Computational Drug Discovery 12.09.13 Cambridge, UK More science events from
Advertisement
Scotland is a global leader in the drug discovery and development process. We are home to an established network of 50+ pharmaceutical clinical trials support and Contract Research Organisations (CROs). Explore our drug discovery strengths in; • Neuroscience • Oncology  • Cardiovascular medicine  • Diabetes and metabolic diseases http://www.sdi.co.uk/sectors/life-sciences.aspx
PERSPECTIVES		Top
INNOVATION Extracellular vesicles: biology and emerging therapeutic opportunities Samir EL Andaloussi, Imre Mäger, Xandra O. Breakefield & Matthew J. A. Wood p347 | doi:10.1038/nrd3978 Extracellular vesicles have emerged as important mediators of intercellular communication, and they are now implicated in numerous biological and pathological processes. Here, Wood and colleagues focus on the role of extracellular vesicles in diseases including cancer, HIV and neurodegenerative disorders, and consider how extracellular vesicles might be targeted or directly exploited for therapeutic intervention. Abstract | Full Text | PDF
INNOVATION Implementing personalized cancer genomics in clinical trials Richard Simon & Sameek Roychowdhury p358 | doi:10.1038/nrd3979 Rapid advances in next-generation sequencing (NGS) are facilitating deeper insights into the molecular classifications of cancer and the mechanisms of resistance development, thereby paving the way for a new era of personalized medicine. In this Perspective, Simon and Roychowdhury explore how genomic information can be used in the design of clinical trials for molecularly targeted anticancer drugs as well as for the development of new biomarkers. Abstract | Full Text | PDF
REVIEWS		Top
Platforms for antibiotic discovery Kim Lewis p371 | doi:10.1038/nrd3975 Re-establishing effective platforms for antibiotic discovery is crucial for combating the growing threats from antibiotic resistance. Here, Lewis discusses the lessons learned from the golden era of antibiotic discovery and reasons for the failure of previous platforms, and proposes strategies to create new platforms or revitalize old ones, including harnessing untapped sources of natural products as well as developing species-selective and prodrug antibiotics. Abstract | Full Text | PDF
Advances in the development of new tuberculosis drugs and treatment regimens Alimuddin Zumla, Payam Nahid & Stewart T. Cole p388 | doi:10.1038/nrd4001 Tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide and there is an urgent need for novel therapies and treatment regimens of shorter duration. Here, Zumla, Nahid and Cole discuss current concepts and recent advances in TB drug discovery, development and clinical trial evaluation, and provide an update of new agents and approaches currently being investigated. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.